European Commission approves Array's encorafenib and binimetinib combo for melanoma treatment

European Commission approves Array's encorafenib and binimetinib combo for melanoma treatment

BOULDER -- Array BioPharma Inc . (NASDAQ: ARRY) today announced the European Commission (EC) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of... Read More

Friday September 21, 2018 0 comments Tags: Denver, Array BioPharma, Ron Squarer, encorafenib, binimetinib

Array BioPharma names Carrie S. Cox chair of its board of directors

Array BioPharma names Carrie S. Cox chair of its board of directors

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) today announced Carrie S. Cox has been named chair of its board of directors effective immediately. Cox has been appointed to the Audit and... Read More

Tuesday August 14, 2018 0 comments Tags: Boulder, Array BioPharma, Carrie Cox, Ron Squarer

Array BioPharma: European Medicines Agency recommends approval of melanoma cancer drug

Array BioPharma: European Medicines Agency recommends approval of melanoma cancer drug

BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending... Read More

Monday July 30, 2018 0 comments Tags: Boulder, Array BioPharma, Ron Squarer

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in Oncology for Melanoma to include... Read More

Monday July 16, 2018 0 comments Tags: Boulder, Array BioPharma, melanoma, Ron Squarer, FDA

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI(encorafenib) capsules in combination with MEKTOVI(binimetinib)tablets... Read More

Thursday June 28, 2018 0 comments Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Ron Squarer

Array BioPharma to collaborate with Pfizer on clinical drug trials

Array BioPharma to collaborate with Pfizer on clinical drug trials

BOULDER -- Array BioPharma (Nasdaq: ARRY) today announced it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel... Read More

Tuesday December 19, 2017 0 comments Tags: Boulder, Array BioPharma, Pfizer, Ron Squarer

Array BioPharma announces FDA acceptance to review new melanoma drug applications

Array BioPharma announces FDA acceptance to review new melanoma drug applications

BOULDER -- Array BioPharma (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Applications (NDAs) to support use of the combination of... Read More

Wednesday September 13, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, encorafenib, binimetinib

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

BOULDER -- Array BioPharma (Nasdaq:ARRY) today announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) to support use of the combination of... Read More

Wednesday July 5, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, binimetinib, encorafenib